REGENXBIO Inc. Overview
Pro stress-test →REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. The company is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne, clemidsogene lanparvovec (RGX-121) for MPS II and MPS I in partnership with Nippon Shinyaku, and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy in collaboration with AbbVie.
Strategic Profile
Pro stress-test →2026 is positioned as a transformative year for REGENXBIO as it enters commercial stage with two near-term catalysts from three late-stage assets and a clear path to sustained growth. Advancing multiple late-stage gene therapy programs and forming strategic partnerships position REGENXBIO for commercial growth with reduced financial risk. Strong in-house manufacturing and a favorable regulatory outlook enhance scalability, margins, and expedite revenue realization from first-in-class therapies.
Competitive Landscape
Pro stress-test →REGENXBIO competes with approximately 53 other biotech firms in AAV gene therapy and rare disease treatment. Key competitors include Denali Therapeutics, Rocket Pharmaceuticals, Voyager Therapeutics, and Arvinas in gene therapy and rare disease space. Differentiation comes from licensing its NAV Technology Platform to other biotechnology and pharmaceutical companies and strategic partnerships with Novartis, AbbVie, and Nippon Shinyaku.
Industry Context
REGENXBIO Inc. operates in Biotechnology - Gene Therapy.
Key facts
Founded: 2009 · Headquarters: Rockville, US · Revenue: $161M (TTM) · Market cap: $760M